BIT Stock Overview
A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Biotron Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.017 |
| 52 Week High | AU$0.12 |
| 52 Week Low | AU$0.016 |
| Beta | -0.60 |
| 1 Month Change | -10.53% |
| 3 Month Change | -15.00% |
| 1 Year Change | -81.11% |
| 3 Year Change | -81.72% |
| 5 Year Change | -68.52% |
| Change since IPO | -96.18% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation
Feb 27
We Think Biotron (ASX:BIT) Can Afford To Drive Business Growth
Oct 20We're Not Worried About Biotron's (ASX:BIT) Cash Burn
Jul 06Will Biotron (ASX:BIT) Spend Its Cash Wisely?
Jan 18Will Biotron (ASX:BIT) Spend Its Cash Wisely?
Jul 06Here's Why We're Watching Biotron's (ASX:BIT) Cash Burn Situation
Mar 17Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation
Nov 27Biotron (ASX:BIT) Is In A Good Position To Deliver On Growth Plans
May 26We're Not Very Worried About Biotron's (ASX:BIT) Cash Burn Rate
Feb 10What Can We Conclude About Biotron's (ASX:BIT) CEO Pay?
Dec 19Shareholder Returns
| BIT | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | -2.7% |
| 1Y | -81.1% | 3.1% | 6.5% |
Return vs Industry: BIT underperformed the Australian Biotechs industry which returned 3.1% over the past year.
Return vs Market: BIT underperformed the Australian Market which returned 6.5% over the past year.
Price Volatility
| BIT volatility | |
|---|---|
| BIT Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: BIT has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: BIT's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Michelle Miller | www.biotron.com.au |
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.
Biotron Limited Fundamentals Summary
| BIT fundamental statistics | |
|---|---|
| Market cap | AU$15.34m |
| Earnings (TTM) | -AU$3.44m |
| Revenue (TTM) | AU$1.65m |
9.3x
P/S Ratio-4.5x
P/E RatioIs BIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIT income statement (TTM) | |
|---|---|
| Revenue | AU$1.65m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.65m |
| Other Expenses | AU$5.08m |
| Earnings | -AU$3.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0038 |
| Gross Margin | 100.00% |
| Net Profit Margin | -208.89% |
| Debt/Equity Ratio | 0% |
How did BIT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 01:35 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biotron Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|